Melphalan Zentiva (Melphalan Hydrochloride)

Melphalan is an alkylating agent that forms covalent bonds with DNA, creating cross‑links that block replication and transcription. This DNA damage triggers programmed cell death (apoptosis) preferentially in rapidly dividing cancer cells, thereby limiting tumor growth.

The specific dose of Melphalan Zentiva is determined by the prescribing oncologist based on the patient’s diagnosis, body surface area, renal function, and treatment protocol. Dosing regimens vary and should be individualized by a qualified healthcare professional.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may be excreted in milk and affect the infant. Use only if the potential benefit justifies the risk.

To request Melphalan Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Melphalan shares the DNA‑cross‑linking mechanism of other alkylators such as cyclophosphamide, but it is often preferred for certain hematologic malignancies and specific solid tumors due to its potency and pharmacokinetic profile. Choice of agent depends on disease type, prior therapy, and patient tolerance.

Melphalan Zentiva should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The product must be kept in its original packaging to maintain stability and should be handled by trained personnel using aseptic technique during preparation and administration.

Melphalan Zentiva is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the treatment protocol and patient tolerance, and vital signs are monitored throughout the administration.

The most serious risks include severe myelosuppression leading to infection or bleeding, secondary malignancies, pulmonary toxicity, and renal impairment. Patients should be closely monitored for signs of infection, respiratory distress, and changes in kidney function during therapy.

Melphalan Zentiva is contraindicated in patients with known hypersensitivity to melphalan or its excipients, pregnant or nursing women, and individuals with severe renal or hepatic impairment unless dose adjustments are made. It should also be avoided in patients receiving live vaccines.